Intra-Cellular Therapies Inc ITCI

NAS: ITCI | ISIN: US46116X1019 14/11/2024

87,63 USD (-0,67%)

(-0,67%) 14/11/2024

Grafiek Intra-Cellular Therapies Inc

Grafiek Intra-Cellular Therapies Inc

1 dag1d -0,67%
1 week1w -4,01%
1 maand1m 17,29%
3 maanden3m 16,42%
6 maanden6m 31,10%
1 jaar1j 54,58%
5 jaar5j 871,51%

Intra-Cellular Therapies Inc in het nieuws

Toon enkel gratis nieuws

25 februari 2021 · Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update · Persbericht

24 februari 2021 · Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284 · Persbericht

21 januari 2021 · CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research · Persbericht

5 januari 2021 · Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Profiel Intra-Cellular Therapies Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.intracellulartherapies.com

Hoofdzetel: New York, New York Verenigde Staten

CEO: Sharon Mates

Werknemers: 514

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe